Connect with us

Press Release

ZUBR Has Become a Leader in the NMN Industry at Home and Abroad

Published

on

As the global economy continues to grow and life expectancy continues to rise, the proportion of elderly people aged 65 years and above continues to increase, and global attention to health issues continues to increase. The life expectancy issue has become one of the ultimate problems that mankind has continued to strive to solve in the history of mankind. In recent years, global academic research has shown that NMN has become a consensus anti-aging health care product.

The full name of NMN is β-nicotinamide mononucleotide, which is the precursor for the synthesis of NAD+ (coenzyme I) in the human body. Since NAD+ is a coenzyme for hundreds of important metabolic enzymes in cells, it also participates in many important cellular processes as a signal molecule. It is closely related to energy metabolism, glycolysis, DNA replication and other activities. NMN can increase the level of NAD+ in the body and is considered a health product with anti-aging functions. Compared with other products, NMN products enhance NAD+ and have the advantages of non-toxic side effects and high conversion efficiency. At present, the academic community has confirmed that NMN has the following 10 major functions: support NAD+ production (NAD+ is an indicator of aging in the body), activate longevity protein/gene SIRTUINS, repair DNA damage, support energy production, enhance metabolism, help enhance physical endurance and vitality, and helps improve blood vessel and muscle physiology, helps weight management, helps brain and heart health, helps improve insulin sensitivity, etc.

As one of the world-class academic achievements, Professor David Sinclair of Harvard University used NMN raw materials and published the research results of NAD+ reversing blood aging in the top academic journal “Cell”. From the age of 30, the NAD+ content in the body decreases significantly. At the age of 60, the level of NAD+ is less than a quarter of that of young people. This means that after 60 years of age, there are many biochemical and metabolic reactions in the human body that cannot be efficiently carried out. Therefore, the older the age, the more health problems become.

How to effectively supplement NMN? According to the FDA’s principle of equivalence, a 70Kg adult should be supplemented with 300mg of NMN per day, and an adult with the same amount of NMN needs to eat 32~128kg of edamame, or 54~240kg of broccoli. It is less efficient to supplement NMN through food sources in nature, and NMN products can achieve this effect faster. After taking NMN in the human body, the study found that the NAD+ content in the body increased significantly after 5 minutes, and the supplement effect was significantly improved.

ZUBR® from the United States is a high-tech company focusing on anti-aging research and product development for a long time. Headquartered in New York, USA, ZUBR® brand Slogan is Anti-aging From Young, advocating the life concept of “anti-aging while young”. ZUBR® introduces anti-aging explosives such as NMN to the United States, Europe and Asia, bringing a healthy lifestyle of “anti-aging while young” to hundreds of millions of middle-class people around the world. ZUBR® has the core production qualifications of health care products such as FDA, NSF GMP, and has mastered core production technology. According to the laboratory test results of US Pharmatech, ZUBR® NMN developed by biological enzymatic method has the characteristics of high purity, high absorption and conversion rate, and the effective purity is higher than that of products in the same industry.

At present, ZUBR® has many flagship products such as NMN Pro and NMN Honor, and the product line fully meets the needs of different users. Among them, the NMN Pro product comes in small bottles, which is currently the only product on the market with a weekly pack (14 capsules) as a unit, which is especially suitable for urban white-collar people to carry during their daily commuting. Each bottle of NMN Pro contains 14 high-concentration NMN capsules, which can be used for a week, and each time it is taken, it can supplement 340mg NMN and 100mg resveratrol. NMN Honor provides a more powerful dose of NMN, suitable for reuse in the morning at home. It can supplement 480mg of NMN and 100mg of resveratrol each time. Each bottle provides 90 capsules for 45 days of continuous use.

Overseas, ZUBR® has won praise from a large number of users with its excellent product strength. Bryan Gunn, an automotive industry designer from Ohio, USA, said, “After taking it, I feel my body is full of vitality, my sleep quality has unexpectedly improved, and I feel my mind is clearer”. Dean Norris, a fund manager from Wall Street in New York, United States, said, “Day 1: 2 capsules in the morning, the body has a significant reaction in the afternoon, and fatigue is reduced; Day 2: 2 capsules in the morning, I feel more clear-headed; 4, 5 days: One hour after each consumption, you can feel your mind becomes clearer and no longer tired; 6th and 7th days: More energy and weight loss than before.” Peter Gould, a Java development engineer from California, said, “Since taking it, I have been very stable and sustained vitality throughout the day. This is an experience I haven’t had before trying other health foods.”

ZUBR® officially entered the Asian market in 2019, using word of mouth as the lifeline of the company’s survival and development. At the same time, in combination with the actual needs of the Asian market, the product price is reduced to a level that can be purchased by the general public while meeting the effective dose. We have reason to believe that ZUBR® will soon become the leading brand in the field of anti-aging health food.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

SK Hynix ETFs – 2x Long (SKHX) & 1x Short (SKHZ) from Leverage Shares by Themes Arrive as ADRs Begin Trading

Published

on

Greenwich, Connecticut, July 10th, 2026, FinanceWire

One Trading Day After the Record Nasdaq Debut, Traders Get 2x Long and 1x Short Tools at a 0.75% Fee — With Options on Both Funds Expected Shortly After Launch

SK Hynix’s American Depositary Receipts began trading on Nasdaq today in the largest-ever US listing by a foreign company, an offering recently sized near $28 billion¹ — and US traders are one trading day away from a complete toolkit to act on it. Leverage Shares by Themes confirmed that the Leverage Shares 2x Long SK Hynix Daily ETF (ticker: SKHX) and the Leverage Shares 1x Short SK Hynix Daily ETF (ticker: SKHZ) begin trading on Cboe this coming Tuesday, July 14th.

The Only 1x Short in the Field

Among the leveraged SK Hynix ETFs arriving Monday, SKHZ is expected to be the only 1x, non-leveraged short product — a way to lean bearish or hedge existing exposure without the amplified decay of a -2x fund. SKHX seeks daily investment results, before fees and expenses, corresponding to 200% (2x) of the daily performance of the SK Hynix American Depositary Receipt (Nasdaq: SKHY); SKHZ seeks daily investment results, before fees and expenses, corresponding to -100% (-1x) of that daily performance. Both funds are actively managed and utilize swaps, options, and other derivatives to deliver efficient exposure.

Options Days Away

Options on both SKHX and SKHZ are expected to begin trading within days of the funds’ launch, adding defined-risk strategies and hedging flexibility on top of the funds themselves.

Experience at This Scale

The firm ran the same play around SpaceX’s IPO, launching long and short ETFs — SPCH and SSPC — simultaneously, in a debut that set the record for the biggest first week of trading in ETF history, topping $4 billion in volume over four trading days.² Both SKHX and SKHZ carry a 0.75% management fee, approximately 40% below the category average.³

“Today the market got SK Hynix. On Monday, traders get the tools — long or short, with options right behind, at a fee that respects them,” said Jose C. Gonzalez Navarro, CEO and Co-Founder of Themes ETFs. “As with all of our daily leveraged and inverse products, these are trading vehicles that reset each day, not buy-and-hold instruments — we encourage investors to size positions carefully and know their exit points.”

For more information about these ETFs and other products offered by Leverage Shares by Themes, please visit www.leverageshares.com/us

Definitions:

American Depositary Receipt (ADR): An American Depositary Receipt (ADR) is a negotiable certificate issued by a U.S. depositary bank that represents shares of a foreign company. ADRs trade on U.S. exchanges in U.S. dollars, making it easier for U.S. investors to buy and sell shares of non-U.S. companies.

Options: Options are exchange-traded contracts linked to an underlying security, such as an ETF, that give the holder the right, but not the obligation, to buy (a call option) or sell (a put option) the underlying security at a specified price before or on a specified expiration date. Options can be used to manage risk or express investment views but involve significant risk and are not appropriate for all investors.

Sources:

¹ Bloomberg, “Extreme SK Hynix Stock Swings Add Wild Card to $28 Billion Deal,” July 7, 2026.

² ETF Trends, “ETF Prime: Record Inflows and SpaceX Leveraged ETFs,” July 1, 2026. See also etf.com, “Winner Emerges In SpaceX ETF Race,” June 30, 2026.

³ Source: etf.com. Universe of 308 daily leveraged & inverse ETFs compared to Leverage Shares SKHY short & leveraged ETFs, as of 6/25/26. Expense ratios are subject to change.

For media inquiries, contact:

Arielle Shternfeld

Director of Communications, Themes ETFs

ashternfeld@themesetfs.com

About Themes ETFs

Themes ETFs is a provider of thematic and single-stock leveraged ETFs, focused on delivering innovative, cost-efficient investment tools that allow investors to access the companies and trends shaping the future. Through its Leverage Shares platform, Themes ETFs offers daily leveraged and inverse ETF strategies designed for sophisticated investors and active traders.

For more information, visit www.themesetfs.com and www.leverageshares.com.

INVESTMENT INVOLVES SIGNIFICANT RISK. Fund does not invest directly in the underlying stock. As with any investment, there is a risk that you could lose all or a portion of your investment in the Fund.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about Themes ETFs. To obtain a Fund’s prospectus and summary prospectus call 886-584-3637. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Newly launched Funds have risks associated with a limited operating history.

Because of daily rebalancing and the compounding of each day’s return over time, the return of the Fund for periods longer than a single day will be the result of each day’s returns compounded over the period, which will very likely differ from 200% (for 2x) or -100% (for -1x) of the return of the underlying stock over the same period. The Fund will lose money if the underlying stock performance is flat over time, and as a result of daily rebalancing, the underlying stock’s volatility and the effects of compounding, it is even possible that the Fund will lose money over time while the underlying stock’s performance increases over a period longer than a single day. The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2x, -1x) investment results, understand the risks associated with the use of leverage and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Fund will lose money if the underlying stock’s performance is flat, and it is possible that the Fund will lose money even if the underlying stock’s performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment for all leveraged funds (2x, -1x). For the 2x fund, if the price of the underlying stock falls by more than 50% in one trading day, an investor could lose the full principal value of their investment.

Under the Investment Advisory Agreement between the Adviser and the Trust, on behalf of the Fund (the “Investment Advisory Agreement”), the Adviser has agreed to pay all expenses of the Fund, except for the fee paid to the Adviser pursuant to the Investment Advisory Agreement, interest charges on any borrowings, taxes, brokerage commissions and other expenses incurred in placing orders for the purchase and sale of securities and other investment instruments, acquired fund fees and expenses, accrued deferred tax liability, extraordinary expenses, and distribution (12b-1) fees and expenses.

Past performance does not guarantee future results.

INVESTMENT RISKS: Investing in the Funds involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

Investment in leveraged products may be subject to higher volatility. Fund does not directly invest in the underlying stock. An investment in the Fund involves risk, including the possible loss of principal. The Fund is non-diversified and includes risks associated with the Fund concentrating its investments in a particular industry, sector, or geographic region which can result in increased volatility. The use of derivatives such as futures contracts and swaps is subject to market risks that may cause their price to fluctuate over time. Risks of the Fund include effects of Compounding and Market Volatility Risk, Inverse Risk, Market Risk, Counterparty Risk, Rebalancing Risk, IntraDay Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, and risks specific to the securities of the Underlying Stock and the sector in which it operates. These and other risks can be found in the prospectus.

For periods longer than a single day, the Funds will lose money if SK Hynix has flat performance, and it is possible that the Funds will lose money even if SK Hynix performance increases or decreases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day if the price of SK Hynix rises or falls by more than 50% in one trading day.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (NBBO) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses, or sales charges. One cannot invest directly in an index.

This information is not an offer to sell or a solicitation of an offer to buy shares of any Funds to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction.

Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. The funds are distributed by ALPS Distributors, Inc (1290 Broadway, Suite 1000, Denver, Colorado 80203). ALPS is not affiliated with any mentioned entity. Client brokerage services not offered by ALPS. Please see third party site for more information about any mentioned services. Themes ETFs are not sponsored, endorsed, issued, sold, or promoted by these entities, nor do these entities make any representations regarding the advisability of investing in the Themes ETFs. Neither ALPS Distributors, Inc, Themes Management Company LLC nor Themes ETFs are affiliated with these entities. Themes Management Company LLC and Leverage Shares are affiliates that are under common control. Themes Management Company and Leverage Shares have entered into a licensing agreement in which Leverage Shares licenses the trademark LEVERAGE SHARES to Themes Management Company LLC for use in financial services in the United States.

Contact

Director of Communications
Arielle Shternfeld
Themes ETFs
ashternfeld@themesetfs.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Dubai Health and Rush University System for Health Announce Strategic Collaboration to Advance Quality of Care

Published

on

Dubai, United Arab Emirates, 10th July 2026: Dubai Health has announced a strategic collaboration with Rush University System for Health, one of the leading United States-based academic healthcare systems, ranked among the nation’s top institutions for quality, patient experience, and safety. The agreement is intended to leverage the respective expertise, capabilities, and resources of both academic health systems to support improved patient outcomes and foster continuous learning, in alignment with international best practices.

Dubai Health

The agreement was signed by Dr. Amer Sharif, Chief Executive Officer of Dubai Health and President of Mohammed Bin Rashid University of Medicine and Health Sciences, and Dr. Omar Lateef, President and CEO of Rush University System for Health and Rush University Medical Center, in the presence of His Excellency Dr. Alawi AlSheikh-Ali, Director General of Dubai Health Authority.

The collaboration outlines areas of cooperation spanning clinical programs and care models, quality and patient safety, performance management, digital health, research, and innovation activities. It also encompasses education, training, and workforce development across medical, nursing, allied health, and leadership domains.

Dr. Amer Sharif, said: “We value the opportunity to engage with Rush University System for Health, which brings together two academic health systems united in a shared commitment to advance health for humanity.”

He added: “Through meaningful knowledge exchange and mutual learning, we look forward to delivering better outcomes for the communities we serve while supporting the development of qualified talent across disciplines and reinforcing Dubai’s position as a global healthcare destination.”

Dr. Omar Lateef, said, “This strategic collaboration creates incredible opportunities to view safety, quality, and the patient experience through a global lens — one that fosters a culture defined by best practices over geographic location. While each system has developed a worldwide reputation for excellence, we have much to learn from one another, with the ultimate beneficiaries being our patients.”

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

TrueDAO Raises $10 million in Strategic Funding to Accelerate AI-Powered Financial Infrastructure

Published

on

New York, USA, July 10th, 2026, Chainwire

TrueDAO announced today the completion of a $10 million strategic funding round. The round was led by Brevan Howard Digital, with participation from Zee Prime Capital and Jump Capital. The proceeds will primarily fund core AI protocol development, AI-driven risk control, security audits, global compliance efforts, and the expansion of ecosystem partnerships.

The journey to this milestone began a year ago when the TrueDAO team set out to build a decentralized financial infrastructure driven by smart contracts, on-chain reserves, dynamic adjustment mechanisms, and community governance. The initiative aimed to address challenges in the traditional crypto industry regarding yield sustainability, risk response, reserve transparency, and governance efficiency; since then, the team has successfully developed the core protocol architecture.

TrueDAO is not designed for a single blockchain application; instead, it aims to serve as a modular financial infrastructure, providing global ecosystem projects with liquidity management, reserve management, risk alerts, yield distribution, and governance support.

This funding round will focus on five key areas: refining smart contracts and protocol modules; building AI-driven risk monitoring and stress-testing systems; implementing independent security audits, real-time monitoring, and bug bounty programs; advancing legal and compliance assessments across various jurisdictions; and releasing developer documentation while expanding ecosystem partnerships.

SoLee, Head of Marketing at TrueDAO stated “Raising $10 million is a significant milestone, but it is not the finish line. While capital accelerates development, it cannot replace security, transparent governance, and genuine value creation. We remain committed to building an on-chain financial infrastructure that is auditable, verifiable, and governable.”

Following the funding, TrueDAO will advance its testnet launch, security audits, developer tools, and ecosystem integration plans, while disclosing protocol operations and reserve data in phases. Specific launch dates, token arrangements, and incentive mechanisms will be subject to official announcements and applicable laws.

About TrueDAO

TrueDAO is an AI-driven decentralized autonomous financial infrastructure project. It is dedicated to building an open, transparent, and composable on-chain financial system through the integration of smart contracts, on-chain data, AI risk analysis, dynamic value adjustment, protocol reserves, and DAO governance.

TrueDAO Website: www.truedao.ai

Contact

TrueDAO
info@truedao.ai

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST